A Brief Review on The Molecular Basis of Medullary Thyroid Carcinoma
Authors:
- Ph.D.PHPh.D.
- Mehdi HedayatiMehdi Hedayati
Open Access
- 1 December 2017
- journal article
- review article
- Vol. 18 (4) , 485-492
Abstract
Approximately 5-10% of all thyroid cancers are medullary thyroid carcinomas (MTC). MTC is mainly sporadic in nature, but 20-30% of cases are hereditary. Genetic testing for hereditary MTC is very important for the patient and his family, but the patients must be receiving appropriate genetic counseling. About 98% of patients with hereditary MTC have germline mutations in exons 10, 11, 13, 14, 15, 16 and intron 16 of the REarrangement during transfection (RET) proto-oncogene, but the etiology of the more frequent sporadic form of MTC (sMTC) is not well understood. Recently, it has been reported that apparently sporadic MTC may involve point mutations in BRAF and RAS genes, with an overall prevalence of almost 10%. Also alteration and abnormal expression of miRNA has been described in MTC. In this review, we attempted to mention some mutations and molecular changes in sporadic and hereditary MTC pathogenesis.Keywords
This publication has 51 references indexed in Scilit:
- RET Gene Abnormalities and Thyroid Disease: Who Should be Screened and WhenJournal of Clinical Research in Pediatric Endocrinology, 2013
- Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinomaCurrent Opinion in Oncology, 2012
- Molecular Basis of Medullary Thyroid Carcinoma: The Role of RET PolymorphismsInternational Journal of Molecular Sciences, 2011
- A family presenting with multiple endocrine neoplasia type 2B: A case reportJournal of Medical Case Reports, 2011
- Differential expression of c-Ret in motor neurons versus non-neuronal cells is linked to the pathogenesis of ALSLaboratory Investigation, 2011
- RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC)Clinical Endocrinology, 2011
- MicroRNAs in CancerAnnual Review of Pathology: Mechanisms of Disease, 2009
- MicroRNA Expression Profiling of Thyroid Tumors: Biological Significance and Diagnostic UtilityThe Journal of Clinical Endocrinology & Metabolism, 2008
- Current Management of Medullary Thyroid CancerThe Oncologist, 2008
- Analysis ofRET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomasCancer, 1995